Compugen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Compugen and other ETFs, options, and stocks.

About CGEN

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. 

CEO
Eran Ophir
CEOEran Ophir
Employees
75
Employees75
Headquarters
Holon, Tel Aviv
HeadquartersHolon, Tel Aviv
Founded
1993
Founded1993
Employees
75
Employees75

CGEN Key Statistics

Market cap
246.31M
Market cap246.31M
Price-Earnings ratio
7.39
Price-Earnings ratio7.39
Dividend yield
Dividend yield
Average volume
618.16K
Average volume618.16K
High today
$2.71
High today$2.71
Low today
$2.54
Low today$2.54
Open price
$2.69
Open price$2.69
Volume
261.32K
Volume261.32K
52 Week high
$3.24
52 Week high$3.24
52 Week low
$1.30
52 Week low$1.30

Stock Snapshot

Compugen(CGEN) stock is priced at $2.61, giving the company a market capitalization of 246.31M. It carries a P/E multiple of 7.39.

On 2026-05-21, Compugen(CGEN) stock traded between a low of $2.54 and a high of $2.71. Shares are currently priced at $2.61, which is +2.6% above the low and -3.7% below the high.

The Compugen(CGEN)'s current trading volume is 261.32K, compared to an average daily volume of 618.16K.

In the last year, Compugen(CGEN) shares hit a 52-week high of $3.24 and a 52-week low of $1.30.

In the last year, Compugen(CGEN) shares hit a 52-week high of $3.24 and a 52-week low of $1.30.

CGEN News

TipRanks 7h
Compugen price target lowered to $5 from $13 at Leerink

Leerink lowered the firm’s price target on Compugen (CGEN) to $5 from $13 and keeps an Outperform rating on the shares. Start a conversation with TipRanks’ tru...

TipRanks 2d
Compugen Earnings Call Highlights Trials, Cash Runway - TipRanks

...

Compugen Earnings Call Highlights Trials, Cash Runway - TipRanks
TipRanks 2d
Compugen: Advancing Clinical Pipeline and AstraZeneca Partnership Underpin Buy Rating with Unchanged $4 Price Target

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Compugen and keeping the price target at $4.00. Unlock hedge fund-level data and...

More CGEN News

TipRanks 3d
Compugen Posts Q1 2026 Results, Cites Strong Cash Runway and Pipeline Advances

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 3d
Compugen reports Q1 EPS (8c) vs. (8c) last year

Reports Q1 revenue $2.2M vs. $2.3M last year. Compugen (CGEN) expects that its cash and cash-related balances will be sufficient to fund its operating plans int...

People also own

Based on the portfolios of people who own CGEN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.